Cargando…

Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

Early-stage NSCLC (stages I and II, and some IIIA diseases) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases, with surgery being its main treatment modality. The risk of disease recurrence and cancer-related death, however, remains high among NSCLC patients after complete s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiu, Li-Chung, Lin, Shu-Min, Lo, Yu-Lun, Kuo, Scott Chih-Hsi, Yang, Cheng-Ta, Hsu, Ping-Chih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310081/ https://www.ncbi.nlm.nih.gov/pubmed/34201650 http://dx.doi.org/10.3390/vaccines9070689

Ejemplares similares

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease
por: Chiu, Li-Chung, et al.
Publicado: (2021)

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
por: Lee, Jay M., et al.
Publicado: (2021)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
por: Chang, John Wen-Cheng, et al.
Publicado: (2022)

Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
por: Hsu, Ping-Chih, et al.
Publicado: (2022)

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
por: Huang, Shih‐Hao, et al.
Publicado: (2019)

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
por: Wu, Chiao-En, et al.
Publicado: (2021)

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)

A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
por: Wang, Chin-Chou, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
por: Hsu, Ping-Chih, et al.
Publicado: (2019)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
por: Chu, Chia‐Hsun, et al.
Publicado: (2020)

The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Comparison of repeated surgical resection and radiofrequency ablation for small recurrent hepatocellular carcinoma after primary resection
por: Sun, Wei-Chi, et al.
Publicado: (2017)

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
por: Chiu, Tzu-Hsuan, et al.
Publicado: (2022)

The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
por: Jiang, Long, et al.
Publicado: (2021)

Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation
por: Kuo, Chih-Hsi Scott, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
por: Tang, Yan-Jei, et al.
Publicado: (2022)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie R., et al.
Publicado: (2018)

Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC
por: Antonoff, Mara B., et al.
Publicado: (2022)

Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer
por: Kuo, Chih-Hsi Scott, et al.
Publicado: (2018)

Concomitant Active Tuberculosis Prolongs Survival in Non-Small Cell Lung Cancer: A Study in a Tuberculosis-Endemic Country
por: Kuo, Chih-Hsi, et al.
Publicado: (2012)

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

Surgical Insights Are Essential to Integration of Immune Therapy in Resectable NSCLC
por: Donington, Jessica S.
Publicado: (2021)

Bronchoscopic debulking for endobronchial malignancy: Predictors of recanalization and recurrence
por: Kuo, Scott Chih-Hsi, et al.
Publicado: (2015)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
por: Wu, Chiao-En, et al.
Publicado: (2022)

Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab
por: Ko, How-Wen, et al.
Publicado: (2022)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
por: Lee, Suey-Haur, et al.
Publicado: (2022)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study
por: Hsu, Ping‐Chih, et al.
Publicado: (2019)

CS-PEI/Beclin-siRNA Downregulate Multidrug Resistance Proteins and Increase Paclitaxel Therapeutic Efficacy against NSCLC
por: Liu, Wangta, et al.
Publicado: (2019)

Diagnostic Value of EBUS-TBNA for Lung Cancer with Non-Enlarged Lymph Nodes: A Study in a Tuberculosis-Endemic Country
por: Kuo, Chih-Hsi, et al.
Publicado: (2011)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j7rjadfdsiv8i696u2drjet47i